BidaskClub upgraded shares of Horizon Pharma (NASDAQ:HZNP) from a hold rating to a buy rating in a research report released on Friday.

HZNP has been the topic of a number of other reports. Piper Jaffray Companies set a $18.00 price target on shares of Horizon Pharma and gave the stock a buy rating in a research report on Sunday, September 10th. Mizuho reaffirmed a hold rating and issued a $12.00 price objective (up previously from $9.00) on shares of Horizon Pharma in a report on Monday, August 28th. Zacks Investment Research cut shares of Horizon Pharma from a hold rating to a sell rating in a report on Tuesday, October 10th. ValuEngine cut shares of Horizon Pharma from a buy rating to a hold rating in a report on Friday, September 1st. Finally, Jefferies Group increased their price objective on shares of Horizon Pharma from $16.00 to $21.00 and gave the stock a buy rating in a report on Tuesday, November 7th. One research analyst has rated the stock with a sell rating, two have given a hold rating and twelve have given a buy rating to the company. The company presently has a consensus rating of Buy and a consensus target price of $18.75.

Horizon Pharma (HZNP) opened at $14.90 on Friday. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.64 and a quick ratio of 1.52. Horizon Pharma has a 52-week low of $9.45 and a 52-week high of $18.31. The stock has a market cap of $2,440.00, a PE ratio of -4.90, a PEG ratio of 1.28 and a beta of 1.31.

Horizon Pharma (NASDAQ:HZNP) last posted its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported $0.26 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.22 by $0.04. Horizon Pharma had a negative net margin of 45.28% and a positive return on equity of 20.22%. The company had revenue of $271.60 million for the quarter, compared to the consensus estimate of $259.74 million. During the same period last year, the firm posted $0.70 EPS. The company’s revenue for the quarter was up 30.1% on a year-over-year basis. research analysts anticipate that Horizon Pharma will post 0.72 earnings per share for the current year.

Institutional investors have recently added to or reduced their stakes in the business. Sheaff Brock Investment Advisors LLC grew its stake in shares of Horizon Pharma by 5.0% in the 2nd quarter. Sheaff Brock Investment Advisors LLC now owns 10,500 shares of the biopharmaceutical company’s stock worth $125,000 after purchasing an additional 500 shares during the last quarter. Prudential Financial Inc. grew its stake in shares of Horizon Pharma by 5.0% in the 2nd quarter. Prudential Financial Inc. now owns 17,510 shares of the biopharmaceutical company’s stock worth $208,000 after purchasing an additional 830 shares during the last quarter. Amalgamated Bank grew its stake in shares of Horizon Pharma by 4.8% in the 2nd quarter. Amalgamated Bank now owns 20,711 shares of the biopharmaceutical company’s stock worth $246,000 after purchasing an additional 943 shares during the last quarter. Bank of Montreal Can grew its stake in shares of Horizon Pharma by 16.3% in the 2nd quarter. Bank of Montreal Can now owns 9,809 shares of the biopharmaceutical company’s stock worth $116,000 after purchasing an additional 1,378 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its stake in shares of Horizon Pharma by 1.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 125,933 shares of the biopharmaceutical company’s stock worth $1,495,000 after purchasing an additional 1,379 shares during the last quarter. 86.58% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Horizon Pharma (HZNP) Lifted to “Buy” at BidaskClub” was originally reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://theolympiareport.com/2017/12/25/horizon-pharma-hznp-lifted-to-buy-at-bidaskclub.html.

About Horizon Pharma

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Analyst Recommendations for Horizon Pharma (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.